PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32272148-0	2020	Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.	osimertinib	45-56	desmoglein 2	Homo sapiens	0-12	
32272148-3	2020	Notably, DSG2 overexpression promoted cell proliferation and migration, and increased resistance to the EGFR tyrosine kinase inhibitor osimertinib, whereas DSG2 silencing could reverse these results.	osimertinib	135-146	desmoglein 2	Homo sapiens	9-13	
32272148-6	2020	Consistent with these findings, a nude mouse xenograft model using H1975 cells demonstrated that DSG2 promoted LUAD cell growth in vivo and increased osimertinib resistance.	osimertinib	150-161	desmoglein 2	Homo sapiens	97-101